Shares in medical technology developer LBT Innovations have jumped more than 20 per cent after a US trial of its culture plate analysis technology exceeded expectations.
The trial results showed that the automated plate assessment system (APAS) achieved more than 98 per cent sensitivity in detecting disease-causing bacteria in urine samples from 5,500 patients.
The culture plates were processed by APAS and simultaneously assessed by a panel of three microbiologists.
"The results of this major trial far exceeded our expectations and confirm that our ground-breaking technology can match the performance of a highly-trained microbiologist," LBT chief executive Lusia Guthrie said on Wednesday.
"The fact that APAS rated so well shows that LBT's technology can be relied upon to replace a repetitive process that accounts for thousands of man-hours in laboratories around the world."
LBT is seeking approval from the US Food and Drug Administration for a manual version of the culture plate analysis technology while a robotic plate-handling system is developed in Europe.
Urine samples represent about 55 per cent of all human samples tested by microbiology laboratories globally.
But many of the samples show no microbial growth or insignificant growth.
The LBT screening mechanism separates samples with no significant microbial growth.
This enables microbiologists to concentrate on the plates with significant growth that hold the key to disease diagnosis.
Shares in LBT closed 2.5 cents, or 23.81 per cent, higher at 13.0 cents.
Share
